Ependymoma clinical trials
The registry lists 179 studies for Ependymoma across more than 10 countries. 35 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-23.
Status
- Completed
- 80
- Active, not recruiting
- 26
- Recruiting
- 26
- Terminated
- 25
- Withdrawn
- 9
- Not yet recruiting
- 9
Phase
- Phase 2
- 74
- Phase 1
- 74
- Early Phase 1
- 6
- Phase 3
- 4
Where
- United States
- 143
- Canada
- 19
- Puerto Rico
- 14
- Australia
- 12
- Spain
- 9
- United Kingdom
- 9
Who runs them
National Cancer Institute (NCI) (47) · Children's Oncology Group (8) · M.D. Anderson Cancer Center (6) · St. Jude Children's Research Hospital (6) · Pediatric Brain Tumor Consortium (5) · City of Hope Medical Center (4) · Beijing Tiantan Hospital (3) · Universitätsklinikum Hamburg-Eppendorf (3)
Studies
Recruiting first, then most recently updated. Showing 50 of 179 — search for more.
- Pharmacoscopy for Patients With Refractory Primary Brain TumorsRecruitingNCT06804655Phase 21 country
- Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade GliomaRecruitingNCT07061626Phase 11 country
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingNCT01356290Phase 28 countries
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingNCT03911388Phase 11 country
- B7-H3.CD28Z.CART in CNS NeoplasmsRecruitingNCT07390539Phase 11 country
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 21 country
- Natural History Study of Patients With Neurofibromatosis Type 2RecruitingNCT005983511 country
- PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsRecruitingNCT06161519Phase 1/21 country
- Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and EpendymomaRecruitingNCT05057702Not applicable1 country
- AI-Assisted MRI Molecular Subtyping in Pediatric Brain TumorsNot yet recruitingNCT07703605
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsRecruitingNCT05278208Phase 1/21 country
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingNCT07713745Phase 21 country
- Selumetinib for NF2-Related SchwannomatosisNot yet recruitingNCT07707947Phase 21 country
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)RecruitingNCT06193759Phase 11 country
- ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS TumorsRecruitingNCT04732065Phase 13 countries
- Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-BeingNot yet recruitingNCT07628647Not applicable1 country
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/21 country
- Intratumoral DNX-2401 for High Grade Pediatric Brain TumorsRecruitingNCT07424092Phase 22 countries
- LET Optimized IMPT in Treating Pediatric Patients With EpendymomaRecruitingNCT03750513Phase 11 country
- Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric TumorsNot yet recruitingNCT07589361
- A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A EpendymomaNot yet recruitingNCT07567469Phase 1/2
- Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System TumorsRecruitingNCT04185038Phase 11 country
- MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion AssessmentRecruitingNCT05957679Not applicable1 country
- Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerRecruitingNCT05106296Phase 11 country
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsRecruitingNCT04541082Phase 11 country
- Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO ClassificationRecruitingNCT0525960512 countries
- International HIT-MED Registry (I-HIT-MED)RecruitingNCT024173241 country
- Systemic Biomarkers to Predict Radiation-Induced Neurocognitive DeclineRecruitingNCT067794871 country
- Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and GliomasNot yet recruitingNCT06323408
- Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncologyRecruitingNCT046484621 country
- In Vitro Models From Pediatric Brain TumorsNot yet recruitingNCT064996361 country
- Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and EpendymomaNot yet recruitingNCT06485908Phase 1/2
- Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa EpendymomaRecruitingNCT03572530Phase 11 country
- An International Clinical Program for the Diagnosis and Treatment of Children With EpendymomaRecruitingNCT02265770Phase 2/315 countries
- Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in ChinaRecruitingNCT056720431 country
- Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade GliomaActive, not recruitingNCT07031765Phase 11 country
- Rare CNS Tumors Outcomes &RiskCompletedNCT032519891 country
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 22 countries
- Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System TumorsCompletedNCT014452881 country
- Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 22 countries
- PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and EpendymomaSuspendedNCT06639607Phase 1/21 country
- Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersTerminatedNCT03173950Phase 21 country
- Phase I Study of APX005M in Pediatric Central Nervous System TumorsCompletedNCT03389802Phase 11 country
- Social Determinants of Health in Glioblastoma PopulationCompletedNCT039006891 country
- Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 23 countries
- 131I-Omburtamab, in Recurrent Medulloblastoma and EpendymomaActive, not recruitingNCT04743661Phase 21 country
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 24 countries
- Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 12 countries
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 22 countries
- Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas SystemCompletedNCT04743310Phase 21 country